John F. Milligan - Jun 17, 2025 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Director
Signature: /s/ Scott Bizily as Attorney-in-Fact for John F. Milligan
Stock symbol: FDMT
Transactions as of: Jun 17, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/20/2025, 04:03 PM
Previous filing: Jun 6, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MILLIGAN JOHN F	Director	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE	/s/ Scott Bizily as Attorney-in-Fact for John F. Milligan	2025-06-20	0001191589

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Award	$0	+33.8K		$0.00	33.8K	Jun 17, 2025	Common Stock	33.8K	$4.15	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2	The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Content

Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).